Home
>
US Stocks
>
Durect Corp
Durect Corp
DRRX

Durect Corp

$1.29.09%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
1.28
Today Low/High
1.18 / 1.28
52 Week Low/High
$1.2 / $2.95
P/E ratio
-11.4442
Market Cap
$277.55M

Company Details

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.
Organisation
Durect Corp
Headquaters
Cupertino, California, US
Employees
81
Industry
Health Technology
CEO
James Brown

Discover more

Frequently Asked Questions

What is Durect Corp share price today

Can Indians buy Durect Corp shares?

How can I buy Durect Corp shares from India?

Can Fractional shares of Durect Corp be purchased?

What are the documents required to start investing in Durect Corp stocks?

We are a SEBI registered investement advisor